Brown tumor is a non-neoplastic bone lesion that develops secondary to hyperparathyroidism and it is very rare in the maxillofacial region. We report the case of a 59-year-old man who presented with pain and a swelling in the left cheek. Computed tomography (CT) demonstrated an expansile and radioluscent lesion in the left maxillary sinus. Incisional biopsy was performed, and the diagnosis was Brown tumor. Brown tumor must be considered in the differential diagnosis of expansile lesions of maxillary sinus.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3883272 | PMC |
| http://dx.doi.org/10.4103/2156-7514.122325 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tellurium nanoparticles and Fucoidan-loaded dissolvable microneedles for combined photothermal therapy and anti-angiogenesis in melanoma treatment.
Int J Biol Macromol
December 2024
School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou 510006, China. Electronic address:
Melanoma, an aggressive skin tumor, is prone to metastasis, significantly reducing patient survival rates once it occurs. Tumor microvascularity is a key factor in metastasis, making the inhibition of microvascular formation crucial. Emerging photothermal therapy (PTT) and microneedles (MNs) have garnered attention due to their non-invasive and controllable nature.
View Article and Find Full Text PDFTatton-Brown-Rahman syndrome: a new multiple endocrine neoplasia syndrome with intellectual disability?
Ann Endocrinol (Paris)
December 2024
GCS AURAGEN, 69003 Lyon, France.
We describe for the first time the case of a woman presenting with Tatton-Brown-Rahman syndrome (TBRS) and multiple endocrine neoplasia (MEN). She developed primary hyperparathyroidism at age 13, a pituitary cyst at age 14, adrenal tumor at age 21, and metastatic insulinoma at age 34. In addition, she showed intellectual disability, obesity, multiple lipomas, facial dysmorphia, hemihypertrophy and kyphoscoliosis.
View Article and Find Full Text PDFCoupling of response biomarkers between tumor and peripheral blood in patients undergoing chemoimmunotherapy.
Cell Rep Med
December 2024
National Centre for Asbestos Related Diseases, Institute for Respiratory Health, Nedlands, WA 6009, Australia; School of Biomedical Sciences, University of Western Australia, Crawley, WA 6009, Australia; The Kids Research Institute, University of Western Australia, Nedlands WA 6009, Australia. Electronic address:
Platinum-based chemotherapy in combination with anti-PD-L1 antibodies has shown promising results in mesothelioma. However, the immunological mechanisms underlying its efficacy are not well understood and there are no predictive biomarkers to guide treatment decisions. Here, we combine time course RNA sequencing (RNA-seq) of peripheral blood mononuclear cells with pre-treatment tumor transcriptome data from the single-arm, phase 2 DREAM trial (N = 54).
View Article and Find Full Text PDFReply.
AJNR Am J Neuroradiol
December 2024
Department Neuro-OncologyErasmus MC Cancer InstituteRotterdam, The Netherlands.
Adjuvant hormone therapy and overall survival among low-grade and apparent early-stage endometrial stromal sarcoma patients.
J Gynecol Oncol
December 2024
Division of Epidemiology, College of Public Health, The Ohio State University, Columbus, OH, USA.
Objective: Surgery is the mainstay of treatment for low-grade endometrial stromal sarcoma (LG-ESS). While adjuvant hormone therapy is recommended for patients with advanced/recurrent disease, no consensus regarding its use among early-stage patients exists. We aimed to identify correlates of adjuvant hormone therapy use and associations of adjuvant hormone therapy and overall survival (OS) in stage I LG-ESS patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!